SFA Therapeutics Receives Orphan Drug Designation for Liver Cancer Drug

November 5, 2019

The FDA granted SFA Therapeutics orphan drug designation for SFA001 to treat hepatocellular carcinoma, the most common type of primary liver cancer.

SFA001 has received two patents, and animal tests have shown that the drug blocked the progression of hepatitis B to hepatocellular carcinoma and demonstrated a non-chemotoxic mechanism of action.

The orphan drug designation “will provide SFA Therapeutics with significant drug development and tax advantages as well as an expanded period of market exclusivity” said Ira Spector, SFA Therapeutics' CEO.

View today's stories